In a prospective , double-blind , 96-week trial , patients were randomly assigned ( 1:1 ) to groups given TDF ( 300 mg , n = 141 ) or a combination of emtricitabine ( FTC , 200 mg ; n = 139 ) and TDF ( 300 mg , FTC/TDF ) .